{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:38:25Z","timestamp":1792820305882,"version":"4.5.0"},"reference-count":18,"publisher":"The Fukushima Society of Medical Science","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.5387\/fms.26-00051","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:09:52Z","timestamp":1792447792000},"source":"Crossref","is-referenced-by-count":0,"title":["Whole-body MRI with DWIBS and choline PET\/CT for detecting oligoprogressive castration-resistant prostate cancer recurrence"],"prefix":"10.5387","author":[{"given":"Kazuhiro","family":"Kitajima","sequence":"first","affiliation":[{"name":"Department of Radiology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shinkai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Kanematsu","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Radiology, Chibune General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hyogo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population based randomized controlled trial. Eur Urol, <b>51<\/b> : 659-664, 2007.","DOI":"10.1016\/j.eururo.2006.07.012"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Freedland SJ, Humphreys EB, Mangold LA, <i>et al<\/i><i>.<\/i> Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA, <b>294<\/b> : 433-439, 2005.","DOI":"10.1001\/jama.294.4.433"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Heidenreich A, Aus G, Bolla M, <i>et al<\/i><i>.<\/i> European Association of Urology. EAU Guidelines on prostate cancer. Eur Urol, <b>53<\/b> : 68-80, 2008.","DOI":"10.1016\/j.eururo.2007.09.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lecouvet FE, El Mouedden J, Collette L, <i>et al<\/i><i>.<\/i> Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol, <b>62<\/b> : 68-75, 2012.","DOI":"10.1016\/j.eururo.2012.02.020"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Van Nieuwenhove S, Van Damme J, Padhani AR, <i>et al<\/i><i>.<\/i> Whole-body magnetic resonance imaging for prostate cancer assessment : Current status and future directions. J Magn Reson Imaging, <b>55<\/b> : 653-680, 2022.","DOI":"10.1002\/jmri.27485"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology. Jpn J Radiol, <b>34<\/b> : 470-485, 2016.","DOI":"10.1007\/s11604-016-0553-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fendler WP, Eiber M, Beheshti M, <i>et al<\/i><i>.<\/i> PSMA PET\/CT : joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging, <b>50<\/b> : 1466-1486, 2023.","DOI":"10.1007\/s00259-022-06089-w"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Evangelista L, Zattoni F, Guttilla A, <i>et al<\/i><i>.<\/i> Choline PET or PET\/CT and biochemical relapse of prostate cancer : a systematic review and meta-analy sis. Clin Nucl Med, <b>38<\/b> : 305-314, 2013.","DOI":"10.1097\/RLU.0b013e3182867f3c"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kitajima K, Murphy RC, Nathan MA. Choline PET\/CT for imaging prostate cancer : an update. Ann Nucl Med. <b>27<\/b> : 581-591, 2013.","DOI":"10.1007\/s12149-013-0731-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Morigi JJ, Stricker PD, van Leeuwen PJ, <i>et al<\/i><i>.<\/i> Prospective Comparison of <sup>18<\/sup>F-Fluoromethylcholine Versus <sup>68<\/sup>Ga-PSMA PET\/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. J Nucl Med, <b>56<\/b> : 1185-1190, 2015.","DOI":"10.2967\/jnumed.115.160382"},{"key":"11","unstructured":"11. Mottet N, van den Bergh RCN, Briers E, Expert Patient Advocate (European Prostate Cancer Coalition\/Europa UOMO). EAU Guidelines. https:\/\/uroweb.org\/guidelines\/2019."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Perera M, Papa N, Roberts M, <i>et al<\/i><i>.<\/i> Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions : a systematic review and meta. Eur Urol, <b>77<\/b> : 403-417, 2020.","DOI":"10.1016\/j.eururo.2019.01.049"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer : a systematic review and meta-analysis. Prostate Cancer Prostatic Dis, <b>26<\/b> : 240-248, 2023.","DOI":"10.1038\/s41391-022-00544-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lecouvet FE, El Mouedden J, Collette L, <i>et al<\/i><i>.<\/i> Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol, <b>62<\/b> : 68-75, 2012.","DOI":"10.1016\/j.eururo.2012.02.020"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Anttinen M, Ettala O, Malaspina S, <i>et al<\/i><i>.<\/i> A prospective comparison of <sup>18<\/sup>F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion weighted imaging, and single-photon emission computed tomography\/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol, <b>4<\/b> : 635-644, 2021.","DOI":"10.1016\/j.euo.2020.06.012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ost P, Reynders D, Decaestecker K, <i>et al<\/i><i>.<\/i> Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence : A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol, <b>36<\/b> : 446-453, 2018.","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tamihardja J, Zehner L, Hartrampf P, <i>et al<\/i><i>.<\/i> Salvage Nodal Radiotherapy as Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer Detected by Positron Emission Tomography Shows Favorable Outcome in Long-Term Follow-Up. Cancers (Basel), <b>14<\/b> : 3766, 2022.","DOI":"10.3390\/cancers14153766"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bauersachs L, Beck M, Furth C, <i>et al<\/i><i>.<\/i> Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic\/oligoprogressive castration resistant prostate cancer. Sci Rep, <b>15<\/b> : 27153, 2025.","DOI":"10.1038\/s41598-025-09622-7"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/advpub\/0\/advpub_26-00051\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:07:59Z","timestamp":1792818479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/advpub\/0\/advpub_26-00051\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"URL":"https:\/\/doi.org\/10.5387\/fms.26-00051","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26-00051"}}